Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
To assess the safety and efficacy of CARTBCMA ARI0002h in patients with relapsed/refractory multiple myeloma who have received treatment with proteasome inhibitor, immunomodulatory drug and anti-CD38 monoclonal antibody.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
73 participants in 1 patient group
Loading...
Central trial contact
Sara Varea, BSc; Carlos Fernandez de Larrea, MD, PhD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal